References and Notes
1. Van den Berg M, Birnbaum L, Bosveld AT, Brunstrom B, Cook P, Feeley M, Giesy JP, Hanberg A, Hasegawa R, Kennedy SW, et al. Toxic equivalency factors (TEFs) for PCBs, PCDDs, PCDFs for humans and wildlife. Environ Health Perspect 106:775-792 (1998).
2. Higginbotham GR, Huang A, Firestone D, Verrett J, Ress J, Campbell AD. Chemical and toxicological evaluations of isolated and synthetic chloro derivatives of dibenzo-p-dioxin. Nature 220:702-703 (1968).
3. Kimbrough RD. Toxicity of chlorinated hydrocarbons and related compounds: a review including chlorinated dibenzodioxins and chlorinated dibenzofurans. Arch Environ Health 25:125-131 (1972).
4. Schwetz BA, Norris JM, Sparschu GL, Rowe VK, Gehring PJ, Emerson JL, Gerbig CG. Toxicology of chlorinated dibenzo-p-dioxins. Environ Health Perspect 5:87-99 (1973).
5. WHO working group. Polychlorinated Dibenzo-para-dioxins and Dibenzofurans. Environmental Health Criteria No. 88. Geneva:World Health Organization, 1989.
6. Dragan YP, Schrenk D. Animal studies addressing the carcinogenicity of TCDD (or related compounds) with an emphasis on tumour promotion. Food Addit Contam 17:289-302 (2000).
7. Fischer B. Receptor-mediated effects of chlorinated hydrocarbons. Andrologia 32:279-283 (2000).
8. Yonemoto J. The effects of dioxin on reproduction and development. Ind Health 38:259-268 (2000).
9. DHHS. Toxicological Profile for Chlorinated Dibenzo-p-Dioxins (update). Public Health Service Agency for Toxic Substances and Disease Registry. No. 205-93-0606. Atlanta, GA:U.S. Department of Health and Human Services, 1998.
10. Leung HW, Murray FJ, Paustenbach DJ. A proposed occupational exposure limit for 2,3,7,8-tetrachlorodibenzo-p-dioxin. Am Ind Hyg Assoc J 49:466-474 (1988).
11. Yunker MB, Cretney WJ. Chlorinated dioxin trends between 1987 and 1993 for samples of crab hepatopancreas from pulp and paper mill and harbour sites in British Columbia. Canadian Technical Report of Fisheries and Aquatic Sciences No. 2082. Ottawa, Ontario, Canada:Fisheries and Oceans Canada, 1995.
12. Cooney CM. How serious is dioxin's cancer risk? Environ Sci Technol 35:180A-181A (2001).
13. Ebner K, Brewster DW, Matsumura F. Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on serum insulin and glucose levels in the rabbit. J Environ Sci Health B23:427-438 (1988).
14. Birnbaum LS. Health effects of dioxins: people are animals, and vice versa! Organohalogen Compounds 49:101-103 (2000).
15. Granner DK, O'Brien RM. Molecular physiology and genetics of NIDDM. Importance of metabolic staging. Diabetes Care 15:369-395 (1992).
16. Felber JP, Golay A. Regulation of nutrient metabolism and energy expenditure. Metabolism 44(suppl 2):4-9 (1995).
17. Viluksela M, Unkila M, Pohjanvirta R, Tuomisto JT, Stahl BU, Rozman KK, Tuomisto J. Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on liver phosphoenolpyruvate carboxykinase (PEPCK) activity, glucose homeostasis and plasma amino acid concentrations in the most TCDD-susceptible and the most TCDD-resistant rat strains. Arch Toxicol 73:323-336 (1999).
18. Rozman KK. Search for the mechanism of toxicity of dioxins: a lesson in toxicology. Exp Toxicol Pathol 44:473-480 (1992).
19. Unkila M, Pohjanvirta R, Viluksela M, Tuomisto JT, Rozman KK, Tuomisto J. Effect of TCDD on tryptophan and glucose homeostasis in the most TCDD-susceptible and the most TCDD-resistant species, guinea pigs and hamsters. Organohalogen Compounds 25:219-223 (1994).
20. Zober A, Ott MG, Messerer P. Morbidity follow up study of BASF employees exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) after a 1953 chemical reactor incident. Occup Environ Med 51:479-486 (1994).
21. Sweeney MH, Calvert GA, Egeland GM, Fingerhut MA, Halperin WE, Piacitelli LA. Review and update on the results of the NIOSH medical study of workers exposed to chemicals contaminated with 2,3,7,8-tetrachlorodibenzodioxin. Teratog Carcinog Mutagen 17:241-247 (1997-1998).
22. Calvert GM, Sweeney MH, Deddens J, Wall DK. Evaluation of diabetes mellitus, serum glucose, and thyroid function among United States workers exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Occup Environ Med 56:270-276 (1999).
23. Bertazzi PA, Bernucci I, Brambilla G, Consonni D, Pesatori AC. The Seveso studies on early and long-term effects of dioxin exposure: a review. Environ Health Perspect 106 (suppl 2):625-633 (1998).
24. Henriksen GL, Ketchum NS, Michalek JE, Swaby JA. Serum dioxin and diabetes mellitus in veterans of Operation Ranch Hand. Epidemiology 8:252-258 (1997).
25. Michalek JE, Akhtar FZ, Kiel JL. Serum dioxin, insulin, fasting glucose, and sex hormone-binding globulin in veterans of Operation Ranch Hand. J Clin Endocrinol Metab 84:1540-1543 (1999).
26. Longnecker MP, Michalek JE. Serum dioxin level in relation to diabetes mellitus among Air Force veterans with background levels of exposure. Epidemiology 11:44-48 (2000).
27. Michalek JE, Tripathi RC, Caudill SP, Pirkle JL. Investigation of TCDD half-life heterogeneity in veterans of Operation Ranch Hand. J Toxicol Environ Health 35:29-38 (1992).
28. Geyer HJ, Scheunert I, Rapp K, Gebefugi I, Steinberg C, Kettrup A. The relevance of fat content in toxicity of lipophilic chemicals to terrestrial animals with special reference to dieldrin and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Ecotoxicol Environ Saf 26:45-60 (1993).
29. Hu K, Bunce NJ. Metabolism of polychlorinated dibenzo-p-dioxins and related dioxin-like compounds. J Toxicol Environ Health B Crit Rev 2:183-210 (1999).
30. International Classification of Diseases, 9th Revision. Geneva:World Health Organization, 1975.
31. Cranmer M, Louie S, Kennedy RH, Kern PA, Fonseca VA. Exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) is associated with hyperinsulinemia and insulin resistance. Toxicol Sci 56:431-436 (2000).
32. Tritscher AM, Clark GC, Sewall C, Sills RC, Maronpot R, Lucier GW. Persistence of TCDD-induced hepatic cell proliferation and growth of enzyme altered foci after chronic exposure followed by cessation of treatment in DEN initiated female rats. Carcinogenesis 16:2807-2811 (1995).
33. Rier SE, Coe CL, Lemieux AM, Martin DC, Morris R, Lucier GW, Clark GC. Increased tumor necrosis factor-alpha production by peripheral blood leukocytes from TCDD-exposed rhesus monkeys. Toxicol Sci 60:327-337 (2001).
34. Wilson CL, Safe S. Mechanisms of ligand-induced aryl hydrocarbon receptor-mediated biochemical and toxic responses. Toxicol Pathol 26:657-671 (1998).
35. Tian Y, Ke S, Denison MS, Rabson AB, Gallo MA. Ah receptor and NF-*B interactions, a potential mechanism for dioxin toxicity. J Biol Chem 274:510-515 (1999).
36. Puga A, Barnes SJ, Dalton TP, Chang C, Knudsen ES, Maier MA. Aromatic hydrocarbon receptor interaction with the retinoblastoma protein potentiates repression of E2F-dependent transcription and cell cycle arrest. J Biol Chem 275:2943-2950 (2000).
37. Nguyen TA, Hoivik D, Lee JE, Safe S. Interactions of nuclear receptor coactivator/corepressor proteins with the aryl hydrocarbon receptor complex. Arch Biochem Biophys 367:250-257 (1999).
38. Rushing SR, Wong C-W, Privalsky ML, Denison MS. SMRT mediated transcriptional silencing of the Ah receptor signaling pathway not observed in human MCF-7 or BG-1 cell lines. Organohalogen Compounds 49:41-43 (2000).
39. Clay CE, Namen AM, Fonteh AN, Atsumi G, High KP, Chilton FH. 15-Deoxy-d12,14 PGJ2 induces diverse biological responses via PPAR
activation in cancer cells. Prostaglandins Other Lipid Mediat 62:23-32 (2000).
40. Greene ME, Pitts J, McCarville MA, Wang XS, Newport JA, Edelstein C, Lee F, Ghosh S, Chu S. PPAR
: observations in the hematopoietic system. Prostaglandins Other Lipid Mediat 62:45-73 (2000).
41. Shimaya A, Kurosaki E, Shioduka K, Nakano R, Shibasadi M, Shikama H. YM268 increases the glucose uptake, cell differentiation, and mRNA expression of glucose transporter in 3T3-L1 adipocytes. Horm Metab Res 30:543-548 (1998).
42. Ahuja HS, Liu S, Crombie DL, Boehm M, Leibowitz MD, Heyman RA, Depre C, Nagy L, Tontonoz P, Davies PJ. Differential effects of rexinoids and thiazolidinediones on metabolic gene expression in diabetic rodents. Mol Pharmacol 59:765-773 (2001).
43. Alexander DL, Ganem LG, Fernandez-Salguero P, Gonzalez F, Jefcoate CR. Aryl-hydrocarbon receptor is an inhibitory regulator of lipid synthesis and of commitment to adipogenesis. J Cell Sci 111:3311-3322 (1998).
44. Enan E, Liu PC, Matsumura F. TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin) causes reduction in glucose uptake through glucose transporters on the plasma membrane of the guinea pig adipocyte. J Environ Sci Health B 27:495-510 (1992).
45. Liu PC, Matsumura F. Differential effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on the "adipose-type" and "brain-type" glucose transporters in mice. Mol Pharmacol 47:65-73 (1995).
46. Simpson F, Whitehead JP, James DE. GLUT4--at the cross roads between membrane trafficking and signal transduction. Traffic 2:2-11 (2001).
47. Murphy GJ, Holder JC. PPAR-* agonists: therapeutic role in diabetes, inflammation and cancer. Trends Pharmacol Sci 21:469-474 (2000).
48. Schoonjans K, Auwerx J. Thiazolidinediones: an update. Lancet 355:1008-1010 (2000).
49. Komers R, Vrana A. Thiazolidinediones--tools for the research of metabolic syndrome X. Physiol Res 47:215-225 (1998).
50. Suzuki A, Yasuno T, Kojo H, Hirosumi J, Mutoh S, Notsu Y. Alteration in expression profiles of a series of diabetes-related genes in db/db mice following treatment with thiazolidinediones. Jpn J Pharmacol 84:113-123 (2000).
51. Fernandez-Real JM, Ricart W. Insulin resistance and inflammation in an evolutionary perspective: the contribution of cytokine genotype/phenotype to thriftiness. Diabetologia 42:1367-1374 (1999).
52. Taylor MJ, Lucier GW, Mahler JF, Thompson M, Lockhart AC. Inhibition of acute TCDD toxicity by treatment with anti-tumor necrosis factor antibody or dexamethasone. Toxicol Appl Pharmacol 117:126-132 (1992).
53. Fan F, Yan B, Wood G, Viluksela M, Rozman KK. Cytokines (IL-1 beta and TNFalpha) in relation to biochemical and immunological effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in rats. Toxicology 116:9-16 (1997).
54. Moos AB, Oughton JA, Kerkvliet NI. The effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on tumor necrosis factor (TNF) production by peritoneal cells. Toxicol Lett 90:145-153 (1997).
55. Yang JH, Vogel C, Abel J. A malignant transformation of human cells by 2,3,7,8-tetrachlorodibenzo-p-dioxin exhibits altered expressions of growth regulatory factors. Carcinogenesis 20:13-18 (1999).
56. Heery DM, Hoare S, Hussain S, Parker MG, Sheppard HM. Core LXXLL motif sequences in CBP, SRC1 and RIP140 define affinity and selectivity for steroid and retinoid receptors. J Biol Chem 276:6695-6702 (2000).
57. Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, Rosenfeld MG, Willson TM, Glass CK, Milburn MV. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 395:137-143 (1998).
58. Webb P, Anderson CM, Valentine C, Nguyen P, Marimuthu A, West BL, Baxter JD, Kushner PJ. The nuclear receptor corepressor (N-CoR) contains three isoleucine motifs (I/LXXII) that serve as receptor interaction domains (IDs). Mol Endocrinol 14:1976-1985 (2000).
59. Ren Y, Behre E, Ren Z, Zhang J, Wang Q, Fondell JD. Specific structural motifs determine TRAP220 interactions with nuclear hormone receptors. Mol Cell Biol 20:5433-5446 (2000).
60. Ko L, Cardona GR, Chin WW. Thyroid hormone receptor-binding protein, an LXXLL motif-containing protein, functions as a general coactivator. Proc Natl Acad Sci USA 97:6212-6217 (2000).
61. Zhu Y, Kan L, Qi C, Kanwar YS, Yeldandi AV, Rao MS, Reddy JK. Isolation and characterization of peroxisome proliferator-activated receptor (PPAR) interacting protein (PRIP) as a coactivator for PPAR. J Biol Chem 275:13510-13516 (2000).
62. Johansson L, Bavner A, Thomsen JS, Farnegardh M, Gustafsson JA, Treuter E. The orphan nuclear receptor SHP utilizes conserved LXXLL-related motifs for interactions with ligand-activated estrogen receptors. Mol Cell Biol 20:1124-1133 (2000).
63. Zhang H, Thomsen JS, Johansson L, Gustafsson JA, Treuter E. DAX-1 functions as an LXXLL-containing corepressor for activated estrogen receptors. J Biol Chem 275:39855-39859 (2000).
64. Kumar MB, Perdew GH. Nuclear receptor coactivator SRC-1 interacts with the Q-rich subdomain of the AhR and modulates its transactivation potential. Gene Exp 8:273-286.
65. Kumar MB, Tarpey RW, Perdew GH. Differential recruitment of coactivator RIP140 by Ah and estrogen receptors. Absence of a role for LXXLL motifs. J Biol Chem 274:22155-22164 (1999).
66. National Library of Medicine. Pubmed. Washington, DC:U.S. Department of Health and Human Services. Available: http://www.ncbi.nlm.nih.gov/ entrez/query.fcgi [cited 19 June 2002].
67. Swiss Institute of Bioinformatics. Database of Protein Families and Domains. Geneva:Swiss Institute of Bioinformatics. Available: http://www.expasy.ch/prosite [cited 19 June 2002].
68. Devine JH, Eubank DW, Clouthier DE, Tontonoz P, Spiegelman BM, Hammer RE, Beale EG. Adipose expression of the phosphoenolpyruvate carboxykinase promoter requires peroxisome proliferator-activated receptor gamma and 9-cis-retinoic acid receptor binding to an adipocyte-specific enhancer in vivo. J Biol Chem 274:13604-13612 (1999).
69. Cassuto H, Aran A, Cohen H, Eisenberger CL, Reshef L. Repression and activation of transcription of phosphoenolpyruvate carboxykinase gene during liver development. FEBS Lett 457:441-444 (1999).
70. Tontonoz P, Hu E, Devine J, Beale EG, Spiegelman BM. PPAR gamma 2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene. Mol Cell Biol 15:351-357 (1999).
71. Viluksela M, Stahl BU, Birnbaum LS, Rozman KK. Subchronic/chronic toxicity of a mixture of four chlorinated dibenzo-p-dioxins in rats II. Biochemical effects. Toxicol Appl Pharmacol 151:70-78 (1998).
72. Brewster DW, Bombick DW, Matsumura F. Rabbit serum hypertriglyceridemia after administration of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). J Toxicol Environ Health 25:495-507 (1988).
73. Kersten S, Wahli W. Peroxisome proliferator activated receptor agonists. In: New Approaches to Drug Delivery (Jolles P, ed). Basel, Switzerland:Birkhauser Publishers, 2000;141-151.
74. Best JD, O'Neal DN. Diabetic dyslipidaemia: current treatment recommendations. Drugs 59:1101-1111 (2000).
75. Lai ZW, Hundeiker C, Gleichmann E, Esser C. Cytokine gene expression during ontogeny in murine thymus on activation of the aryl hydrocarbon receptor by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Mol Pharmacol 52:30-37 (1997).
76. Calleja C, Eeckhoutte C, Larrieu G, Dupuy J, Pineau T, Galtier P. Differential effects of interleukin-1 beta, interleukin-2, and interferon-gamma on the inducible expression of CYP 1A1 and CYP 1A2 cultured rabbit hepatocytes. Biochem Biophys Res Commun 239:273-278 (1997).
77. Charles GD, Shiverick KT. 2,3,7,8-Tetrachlorodibenzo-p-dioxin increases mRNA levels for interleukin-1beta, urokinase plasminogen activator, and tumor necrosis factor-alpha in human uterine endometrial adenocarcinoma RL95-2 cells. Biochem Biophys Res Commun 238:338-342 (1997).
78. Vainio H, Linnainmaa K, Kahonen M, Nickels J, Hietanen E, Marniemi J, Peltonen P. Hypolipidemia and peroxisome proliferation induced by phenoxyacetic acid herbicides in rats. Biochem Pharmacol 32:2775-2779 (1983).
79. Wielandt AM, Vollrath V, Manzano M, Miranda S, Accatino L, Chianale J. Induction of the multispecific organic anion transporter (cMoat/mrp2) gene and biliary glutathione secretion by the herbicide 2,4,5-trichlorophenoxyacetic acid in the mouse liver. Biochem J 341(Pt 1):105-111 (1999).
80. Maloney EK, Waxman DJ. Trans-activation of PPAR
and PPAR
by structurally diverse environmental chemicals. Toxicol Appl Pharmacol 161:209-218 (1999).
Last Updated: July 17, 2002